PHARM ASSOC
GenericsPHARM ASSOC is a generic drug manufacturer focused on Neurology, Gastroenterology, Immunology.
Upcoming FDA Decisions
Full Calendar →PHARM ASSOC's Key Drugs
PHARM ASSOC's core commercial portfolio centers on BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, spanning Neurology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
PHARM ASSOC's Recent FDA Approvals
New NDA/BLA approvals for PHARM ASSOC over the last two years — novel drugs only, excluding generics and label supplements.
PHARM ASSOC's Therapeutic Areas
PHARM ASSOC's approved drugs and pipeline span 4 therapeutic areas, led by Neurology and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PHARM ASSOC's Top Competitors
PHARM ASSOC's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PHARM ASSOC Pipeline Snapshot
Active clinical trials for PHARM ASSOC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1980-06-25
- Latest
- 2026-06-18
- Applications
- 63